1,796,341 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Boxer Capital Management LLC

Boxer Capital Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,796,341 shares of the company's stock, valued at approximately $21,754,000. Replimune Group makes up 1.8% of Boxer Capital Management LLC's investment portfolio, making the stock its 14th biggest holding. Boxer Capital Management LLC owned about 2.63% of Replimune Group at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Victory Capital Management Inc. bought a new stake in shares of Replimune Group during the fourth quarter valued at about $543,000. Swiss National Bank grew its stake in Replimune Group by 57.4% during the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock valued at $1,256,000 after acquiring an additional 37,800 shares in the last quarter. Barclays PLC increased its holdings in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares during the period. Bank of New York Mellon Corp lifted its stake in Replimune Group by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock worth $2,113,000 after purchasing an additional 11,893 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in shares of Replimune Group by 260.8% during the 4th quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock valued at $523,000 after purchasing an additional 31,231 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Down 2.5 %

Replimune Group stock traded down $0.19 during mid-day trading on Wednesday, hitting $7.31. The company's stock had a trading volume of 657,562 shares, compared to its average volume of 885,378. The business has a 50 day moving average price of $9.65 and a 200-day moving average price of $11.57. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a market cap of $562.98 million, a price-to-earnings ratio of -2.39 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Replimune Group presently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.